Recruiting

Phase 2

PemigatinibA Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Sponsor:

Sameek Roychowdhury

Code:

NCT06906562

Conditions

Advanced Pancreatic Carcinoma

Metastatic Pancreatic Carcinoma

Stage II Pancreatic Cancer AJCC v8

Stage III Pancreatic Cancer AJCC v8

Stage IV Pancreatic Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pemigatinib

Computed Tomography (CT)

Magnetic Resonance Imaging

Optical Coherence Tomography

Bone Scan

Study Details

Brief summary:

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body (metastatic) and that have abnormal changes (alterations) in the fibroblast growth factor receptor (FGFR) gene. FGFR genes are genes that, when altered, can lead to and promote the growth of cancer in patients. Researchers want to test if using pemigatinib can block the function of these abnormal FGFR genes and prevent the tumor from growing and whether treatment can help improve overall quality of life.

Conditions

Advanced Pancreatic Carcinoma

Metastatic Pancreatic Carcinoma

Stage II Pancreatic Cancer AJCC v8

Stage III Pancreatic Cancer AJCC v8

Stage IV Pancreatic Cancer AJCC v8

Study ID

NCT06906562

Start date

Aug 26, 2025

Status verified date

Feb, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

Patients with histologically or cytologically confirmed advanced or metastatic pancreatic cancer of any histologic classification at the time of diagnosis

Written documentation of local or central Clinical Laboratory Improvement Act (CLIA)-certified laboratory determination of FGFR gene fusions/translocations or activating mutations
The study is open to pancreatic cancer in the following cohorts:

Cohort 1: Pancreatic cancer of any histology with FGFR2 fusion/translocation (n, up to 30) who have progressed on or are intolerant to at least one standard of care (SOC) therapy. Prior therapy with a different FGFR inhibitor is not permitted. Patients with concurrent Kirsten rat sarcoma (KRAS) mutations are excluded from this cohort
Cohort 2: Pancreatic cancer of any histology with activating point mutations, fusion/translocation (FGFR1,3,4) extracellular small indels, or kinase domain duplications (n, up to 10). Patients must have progressed on or are intolerant to at least one SOC therapy. Prior therapy with a different FGFR inhibitor is not permitted. Patients with concurrent KRAS mutations are permitted in this cohort
Evidence of measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Patients must have received at least one prior SOC regimen for advanced/metastatic pancreas cancer. Patients should have had evidence of progressive disease following their prior regimen, or if prior treatment was discontinued due to toxicity must have continued evidence of measurable or evaluable disease. Patients who have received prior treatment with an alternate FGFR inhibitor are not eligible for the study
Patients with symptomatic central nervous system (CNS) metastases are excluded (because it is unclear how much CNS penetration the drug has). However, asymptomatic patients with history of successfully treated CNS metastases with surgery or radiation and follow up imaging showing stability, can be eligible
Patients ≥ 18 years of age of either gender
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (patients with ECOG performance status of 2 may be considered on a case-by-case basis after discussion with Incyte)
Able to read and/or understand the details of the study and provide written evidence of informed consent as approved by Institutional Review Board (IRB)/Ethics Committee (EC)
Recovery from adverse events of previous systemic anti-cancer therapies to baseline or Grade 1, except for:

Alopecia
Stable neuropathy of ≤ Grade 2 due to prior cancer therapy
Able to swallow and retain oral medication
Willing and able to comply with scheduled visits, treatment plan and laboratory tests

Exclusion Criteria

Neurological symptoms related to underlying disease requiring increasing doses of corticosteroids.

\* Note: Steroid use for management of CNS tumors is allowed but must be at a stable dose for at least 2 weeks preceding study entry

History of another primary malignancy except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the course of the study or affect survival
Any other medical condition that would, in the investigator's , prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
Current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjuctivitis, confirmed by ophthalmologic examination
History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral pemigatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc.
Treatment with any of the following anti-cancer therapies prior to the first dose of pemigatinib within the stated timeframes:

Cyclical chemotherapy (intravenous) within a period of time that is shorter than the cycle length used for that treatment (e.g., 6 weeks for nitrosourea, mitomycin-C)
Biological therapy (e.g., antibodies - including bevacizumab) within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks, whichever is shorter, prior to starting study drug
Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug
Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug
Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug
Patients who are currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration are excluded. Patients are not permitted to receive enzyme-inducing anti-epileptic drugs
Consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, Seville oranges or products within 7 days prior to first dose
Absolute neutrophil count (ANC) ≤ 1,000/mm\^3 \[1.0 x 10\^9/L\]
Platelets ≤ 75,000/mm\^3 \[75 x 10\^9/L\] • Hemoglobin ≤ 9.0 g/dL
Total bilirubin ≥ 1.5x upper limit of normal (ULN) unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 3x ULN unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
Alkaline phosphatase ≥ 2.5x ULN unless associated with patient's primary cancer and/or metastases and with principal investigator's approval
Calculated or measured creatinine clearance of < 40 mL/min
Calcium-phosphate homeostasis:

Inorganic phosphorus outside of institutional normal limits
Total serum calcium (can be corrected) outside of institutional normal limits
History of clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure, or arrhythmia requiring therapy. Subjects with a pacemaker and well-controlled rhythm for at least 1 month prior to first dose will be allowed
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months following the discontinuation of study treatment. Highly effective contraception methods include:

Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine systems (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential
Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after the last dose of the study drug and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via seminal fluid

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Pemigatinib Treament

Patients receive pemigatinib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT and/or MRI, and OCT throughout the study. Patients may also undergo whole body bone scans and dilated fundoscopy as clinically indicated.

Interventions

Pemigatinib

Pemigatinib will be taken orally with a targeted starting does of 13.5 mg

Computed Tomography (CT)

Undergo CT scan

Magnetic Resonance Imaging

Undergo MRI

Optical Coherence Tomography

Undergo OCT

Bone Scan

Undergo whole body bone scan

Ophthalmoscopy

Undergo dilated ophthalmoscopy

Primary outcome measure

Overall Response Rate (ORR) [ Time Frame: Up to 24 months ]

Central Contacts and Locations

Central contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

The Ohio State University Comprehensive Cancer Center and James Cancer Hospital

OSUCCCClinicaltrials@osumc.edu

Locations

Ohio State University-Telemedicine

Recruiting

Birmingham, Alabama, United States, 35205

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Mobile, Alabama, United States, 36604

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Montgomery, Alabama, United States, 36104

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Anchorage, Alaska, United States, 99508

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Flagstaff, Arizona, United States, 86001

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Phoenix, Arizona, United States, 85054

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Tucson, Arizona, United States, 85719

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Hot Springs, Arkansas, United States, 71913

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 Sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Fresno, California, United States, 87901

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Los Angeles, California, United States, 91010

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

San Diego, California, United States, 92037

Contacts

Sameek Roychowdhury, MD, Phd

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

San Francisco, California, United States, 94143

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Denver, Colorado, United States, 80202

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Durango, Colorado, United States, 81301

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Grand Junction, Colorado, United States, 81501

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Sameek Roychowdhury, MD, Phd

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Wilmington, Delaware, United States, 19713

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Washington D.C., District of Columbia, United States, 20007

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Jacksonville, Florida, United States, 32207

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Miami, Florida, United States, 33136

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Orlando, Florida, United States, 32806

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Tallahassee, Florida, United States, 32301

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Tampa, Florida, United States, 33612

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Augusta, Georgia, United States, 30912

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Boise, Idaho, United States, 83706

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Lewiston, Idaho, United States, 83501

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Champaign, Illinois, United States, 61801

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Quincy, Illinois, United States, 62301

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Evansville, Indiana, United States, 44708

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Fort Wayne, Indiana, United States, 46804

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Colby, Kansas, United States, 67701

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Wichita, Kansas, United States, 67206

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Lexington, Kentucky, United States, 40536

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Lake Charles, Louisiana, United States, 70601

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

New Orleans, Louisiana, United States, 70112

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Shreveport, Louisiana, United States, 77101

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Bar Harbor, Maine, United States, 04609

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Baltimore, Maryland, United States, 21231

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Detroit, Michigan, United States, 48201

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Minneapolis, Minnesota, United States, 55455

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Rochester, Minnesota, United States, 55901

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Jackson, Mississippi, United States, 39201

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Springfield, Missouri, United States, 65801

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Bozeman, Montana, United States, 59715

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Miles City, Montana, United States, 59301

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

North Platte, Nebraska, United States, 69101

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Omaha, Nebraska, United States, 68105

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Las Vegas, Nevada, United States, 89166

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Reno, Nevada, United States, 89501

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Concord, New Hampshire, United States, 03301

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Albuquerque, New Mexico, United States, 87102

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Roswell, New Mexico, United States, 88201

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Albany, New York, United States, 12208

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Buffalo, New York, United States, 14021

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

New York, New York, United States, 10065

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Syracuse, New York, United States, 13210

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Charlotte, North Carolina, United States, 28204

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Raleigh, North Carolina, United States, 27614

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Bismarck, North Dakota, United States, 58701

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Fargo, North Dakota, United States, 58103

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Cincinnati, Ohio, United States, 45219

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Comprehensive Cancer Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Sameek Roychowdhury, MD, PhD

614-685-5842 Sameek.Roychowdhury@osumc.edu

Principal Investigator:

Sameek Roychowdhury, MD, PhD

Ohio State University-Telemedicine

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Sameek Roychowdhury, MD, Phd

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Eugene, Oregon, United States, 97401

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Portland, Oregon, United States, 97239

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Philadelphia, Pennsylvania, United States, 48109

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University

Recruiting

Wellsboro, Pennsylvania, United States, 16901

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Sameek Roychowdhur, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Rapid City, South Dakota, United States, 57701

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Sioux Falls, South Dakota, United States, 57101

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Knoxville, Tennessee, United States, 37901

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Memphis, Tennessee, United States, 38119

Contacts

Sameek Roychowdhury, MD, Phd

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Amarillo, Texas, United States, 79101

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Austin, Texas, United States, 78745

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Dallas, Texas, United States, 75208

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Fort Stockton, Texas, United States, 79735

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Houston, Texas, United States, 77030

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Midland, Texas, United States, 79706

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Cedar City, Utah, United States, 84720

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Salt Lake City, Utah, United States, 84112

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Burlington, Vermont, United States, 05401

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Norfolk, Virginia, United States, 02301

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Richmond, Virginia, United States, 23298

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Roanoke, Virginia, United States, 24011

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Seattle, Washington, United States, 98109

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Spokane, Washington, United States, 99201

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Huntington, West Virginia, United States, 25701

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Morgantown, West Virginia, United States, 26506

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Chippewa Falls, Wisconsin, United States, 54729

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Green Bay, Wisconsin, United States, 54301

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Madison, Wisconsin, United States, 53701

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University-Telemedicine

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Sameek Roychowdhury, MD, PhD

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Cheyenne, Wyoming, United States, 82001

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

Ohio State University Telemedicine

Recruiting

Jackson, Wyoming, United States, 83003

Contacts

Sameek Roychowdhury

734-474-8359 sameek.roychowdhury@osumc.edu

More Information

Sponsor

Sameek Roychowdhury

Last update posted

Feb 17, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-19. This information was provided to ClinicalTrials.gov by Sameek Roychowdhury on 2026-02-17.